

(20168)

(Formerly Laboratory Tests for Heart Transplant Rejection)

<b>Medical Benefit</b>		<b>Effective Date:</b> 04/01/19	<b>Next Review Date:</b> 11/19
<b>Preauthorization</b>	No	<b>Review Dates:</b> 05/13, 05/14, 05/15, 05/16, 05/17, 05/18, 11/18	

***This protocol considers this test or procedure investigational. If the physician feels this service is medically necessary, preauthorization is recommended.***

*The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.*

Populations	Interventions	Comparators	Outcomes
Individuals: • With heart transplant	Interventions of interest are: • Measurement of volatile organic compounds to assess cardiac allograft rejection	Comparators of interest are: • Routine endomyocardial biopsy	Relevant outcomes include: • Overall survival • Test validity • Morbid events • Hospitalizations
Individuals: • With heart transplant	Interventions of interest are: • Gene expression profiling to assess cardiac allograft rejection	Comparators of interest are: • Routine endomyocardial biopsy	Relevant outcomes include: • Overall survival • Test validity • Morbid events • Hospitalizations
Individuals: • With renal transplant and clinical suspicion of allograft rejection	Interventions of interest are: • Testing donor-derived cell-free DNA in blood to assess allograft rejection	Comparators of interest are: • Renal biopsy	Relevant outcomes include: • Overall survival • Test validity • Morbid events • Hospitalizations

### DESCRIPTION

Several commercially available laboratory tests assess heart transplant rejection, including the Heartsbreath test, which measures breath markers of oxidative stress, and the AlloMap test, which uses gene expression profiling. These tests create a score based on the expression of a variety of immunomodulatory genes and are proposed as an alternative or as an adjunct to invasive endomyocardial biopsy. Renal transplant rejection may be assessed by the AlloSure test, which measures the donor-derived cell-free DNA in peripheral blood and is proposed as an alternative or as an adjunct to invasive renal biopsy.

### SUMMARY OF EVIDENCE

For individuals who have a heart transplant who receive measurement of volatile organic compounds to assess cardiac allograft rejection, the evidence includes a diagnostic accuracy study. Relevant outcomes are overall sur-

vival, test validity, morbid events, and hospitalizations. The published study found that, for identifying grade 3 (now grade 2R) rejection, the negative predictive value of the breath test the study evaluated (97.2%) was similar to endomyocardial biopsy (96.7%) and the sensitivity of the breath test (78.6%) was better than that for biopsy (42.4%). However, the breath test had a lower specificity (62.4%) and a lower positive predictive value (5.6%) in assessing grade 3 rejection than a biopsy (specificity, 97%; positive predictive value, 45.2%). The breath test was also not evaluated for grade 4 rejection. This single study is not sufficient to determine the clinical validity of the test measuring volatile organic compounds and no studies on clinical utility were identified. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have a heart transplant who receive gene expression profiling (GEP) to assess cardiac allograft rejection, the evidence includes two diagnostic accuracy studies and several randomized controlled trials evaluating clinical utility. Relevant outcomes are overall survival, test validity, morbid events, and hospitalizations. The two studies (CARGO, CARGO II) examining the diagnostic performance of GEP for detecting moderate-to-severe rejection lacked a consistent threshold for defining a positive GEP test (i.e., 20, 30, or 34) and reported a low number of positive cases. In the available studies, although the negative predictive values were relatively high (i.e., at least 88%), the performance characteristics were only calculated based on 10 or fewer cases of rejection; therefore, performance data may be imprecise. Moreover, the positive predictive value in CARGO II was only 4.0% for patients who were at least two to six months posttransplant and 4.3% for patients more than six months posttransplant. The threshold indicating a positive test that seems to be currently accepted (a score of 34) was not prespecified; rather it evolved partway through the data collection period in the Invasive Monitoring Attenuation through Gene Expression (IMAGE) study. In addition, the IMAGE study had several methodologic limitations (e.g., lack of blinding); further, the IMAGE study failed to provide evidence that GEP offers incremental benefit over biopsy performed on the basis of clinical exam or echocardiography. Patients at the highest risk of transplant rejection are patients within one year of the transplant, and, for that subset, there remains insufficient data on which to evaluate the clinical utility of GEP. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with a renal transplant and clinical suspicion of allograft rejection who receive testing of donor-derived cell-free DNA (dd-cfDNA) to assess renal allograft rejection, the evidence includes a diagnostic accuracy study. Relevant outcomes are overall survival, test validity, morbid events, and hospitalizations. The study examined the diagnostic performance of dd-cfDNA for detecting moderate-to-severe rejection; the negative predictive value was moderately high (84%), and performance characteristics were calculated on 27 cases of active transplant rejection. The threshold indicating a positive test was not prespecified. The evidence is insufficient to determine the effects of the technology on health outcomes

## POLICY

The measurement of volatile organic compounds to assist in the detection of moderate grade 2R (formerly grade 3) heart transplant rejection is considered **investigational**.

The use of peripheral blood gene expression profile tests in the management of patients after heart transplantation, including but not limited to the detection of acute heart transplant rejection or heart transplant graft dysfunction, is considered **investigational**.

The use of peripheral blood measurement of donor-derived cell-free DNA in the management of patients after renal transplantation, including but not limited to the detection of acute renal transplant rejection or renal transplant graft dysfunction, is considered **investigational**.

## POLICY GUIDELINES

The U.S. Food and Drug Administration (FDA) has indicated that the Heartsbreath™ (Menssana Research) test is

only for use as an aid in the diagnosis of grade 3 (now known as grade 2R) heart transplant rejection in patients who have received heart transplants within the preceding year and who have had endomyocardial biopsy within the previous month.

### MEDICARE ADVANTAGE

AlloMap™ may be considered **medically necessary** for heart transplant patients to guide therapeutic decision-making.

Any other uses of Allomap are considered **investigational**.

The Heartsbreath™ test is considered **investigational**.

### BACKGROUND

#### HEART TRANSPLANT REJECTION

Most cardiac transplant recipients experience at least a single episode of rejection in the first year after transplantation. The International Society for Heart and Lung Transplantation (2005) modified its grading scheme for categorizing cardiac allograft rejection.<sup>1</sup> The revised (R) categories are listed in Table 1.

Table 1. Revised Grading Schema for Cardiac Allograft Rejection

New Grade	Definition	Old Grade
0R	No rejection	
1R	Mild rejection	1A, 1B, and 2
2R	Moderate rejection	3A
3R	Severe rejection	3B and 4

#### Surveillance

Acute cellular rejection is most likely to occur in the first six months, with a significant decline in the incidence of rejection after this time. Although immunosuppressants are required on a life-long basis, dosing is adjusted based on graft function and the grade of acute cellular rejection determined by histopathology. Endomyocardial biopsies are typically taken from the right ventricle via the jugular vein periodically during the first six to 12 months posttransplant. The interval between biopsies varies among clinical centers. A typical schedule is weekly for the first month, once or twice monthly for the following six months, and several times (monthly to quarterly) between six months and one year posttransplant. Surveillance biopsies may also be performed after the first postoperative year (e.g., on a quarterly or semiannual basis). This practice, although common, has not been demonstrated to improve transplant outcomes. Some centers no longer routinely perform endomyocardial biopsies after one year in patients who are clinically stable.

While endomyocardial biopsy is the criterion standard for assessing heart transplant rejection, it is limited by a high degree of interobserver variability in grading of results and potential morbidity that can occur with the biopsy procedure. Also, the severity of rejection may not always coincide with the grading of the rejection by biopsy. Finally, a biopsy cannot be used to identify patients at risk of rejection, limiting the ability to initiate therapy to interrupt the development of rejection. For these reasons, endomyocardial biopsy is considered a flawed criterion standard by many. Therefore, noninvasive methods of detecting cellular rejection have been explored. It is hoped that noninvasive tests will assist in determining appropriate patient management and avoid overuse or underuse of treatment with steroids and other immunosuppressants that can occur with false-negative and false-positive biopsy reports. Two techniques are commercially available for the detection of heart transplant rejection.

### *Noninvasive Heart Transplant Rejection Tests*

The Heartsbreath test, a noninvasive test that measures breath markers of oxidative stress, has been developed to assist in the detection of heart transplant rejection. In heart transplant recipients, oxidative stress appears to accompany allograft rejection, which degrades membrane polyunsaturated fatty acids and evolving alkanes and methylalkanes that are, in turn, excreted as volatile organic compounds in breath. The Heartsbreath test analyzes the breath methylated alkane contour, which is derived from the abundance of C4 to C20 alkanes and monomethylalkanes and has been identified as a marker to detect grade 3 (clinically significant) heart transplant rejection.

Another approach has focused on patterns of gene expression of immunomodulatory cells, as detected in the peripheral blood. For example, microarray technology permits the analysis of the expression of thousands of genes, including those with functions known or unknown. Patterns of gene expression can then be correlated with known clinical conditions, permitting a selection of a finite number of genes to compose a custom multi-gene test panel, which then can be evaluated using polymerase chain reaction techniques. AlloMap is a commercially available molecular expression test that has been developed to detect acute heart transplant rejection or the development of graft dysfunction. The test involves polymerase chain reaction–expression measurement of a panel of genes derived from peripheral blood cells and applies an algorithm to the results. The proprietary algorithm produces a single score that considers the contribution of each gene in the panel. The score ranges from zero to 40. The AlloMap website states that a lower score indicates a lower risk of graft rejection; the website does not cite a specific cutoff for a positive test.<sup>2</sup> All AlloMap testing is performed at the CareDx reference laboratory in California.

Other laboratory-tested biomarkers of heart transplant rejection have been evaluated. They include brain natriuretic peptide, troponin, and soluble inflammatory cytokines. Most have had low accuracy in diagnosing rejection. Preliminary studies have evaluated the association between heart transplant rejection and micro-RNAs or high-sensitivity cardiac troponin in cross-sectional analyses, but the clinical use has not been evaluated.<sup>3,4</sup>

### RENAL TRANSPLANT REJECTION

Allograft dysfunction is typically asymptomatic and has a broad differential, including graft rejection. Diagnosis and rapid treatment are recommended to preserve graft function and prevent loss of the transplanted organ. For a primary kidney transplant, graft survival at one year is 94.7%; at five years, graft survival is 78.6%.<sup>5</sup>

#### Surveillance

Surveillance of transplant kidney function relies on routine monitoring of serum creatinine, urine protein levels, and urinalysis.<sup>6</sup> Allograft dysfunction may also be demonstrated by a drop in urine output or, rarely, as pain over the transplant site. With clinical suspicion of allograft dysfunction, additional noninvasive workup including ultrasonography or radionuclide imaging may be used. A renal biopsy allows a definitive assessment of graft dysfunction and is typically a percutaneous procedure performed with ultrasonography or computed tomography guidance. Biopsy of a transplanted kidney is associated with fewer complications than biopsy of a native kidney because the allograft is typically transplanted more superficially than a native kidney. Renal biopsy is a low-risk invasive procedure that may result in bleeding complications; loss of a renal transplant, as a complication of renal biopsy, is rare.<sup>7</sup>

Kidney biopsies allow for diagnosis of acute and chronic graft rejection, which may be graded using the Banff Classification.<sup>8,9</sup> Pathologic assessment of biopsies demonstrating acute rejection allows clinicians to further distinguish between acute cellular rejection and antibody-mediated rejection, which are treated differently.

#### Donor-Derived Cell-Free DNA

Cell-free DNA (cfDNA), released by damaged cells, is normally present in healthy individuals.<sup>10</sup> In patients who have received transplants, donor-derived cfDNA (dd-cfDNA) may be also present. It is proposed that allograft

rejection, which is associated with damage to transplanted cells, may result in an increase in dd-cfDNA. AlloSure is a commercially available, next-generation sequencing assay that quantifies the fraction of dd-cfDNA in renal transplant recipients, relative to total cfDNA, by measuring 266 single nucleotide variants. Separate genotyping of the donor or recipient is not required, but patients who receive a kidney transplant from a monozygotic (identical) twin are not eligible for this test. The fraction of dd-cfDNA relative to total cfDNA present in the peripheral blood sample is cited in the report. All AlloSure testing is performed at the CareDx reference laboratory.

## REGULATORY STATUS

In 2004, the Heartsbreath™ test (Menssana Research) was cleared for marketing by the U.S. Food and Drug Administration through a humanitarian device exemption for use as an aid in diagnosing grade 3 heart transplant rejection in patients who have received heart transplants within the preceding year. The device is intended as an adjunct to, and not as a substitute for, endomyocardial biopsy and is also limited to patients who have had endomyocardial biopsy within the previous month.

In 2008, AlloMap® Molecular Expression Testing (CareDx, formerly XDx) was cleared for marketing by the Food and Drug Administration through the 510(k) process. The Food and Drug Administration determined that this device was substantially equivalent to existing devices, in conjunction with clinical assessment, for aiding in the identification of heart transplant recipients with stable allograft function and a low probability of moderate-to-severe transplant rejection. It is intended for patients at least 15 years old who are at least two months post-transplant.

## RELATED PROTOCOLS

Heart Transplant

Heart/Lung Transplant

---

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

## REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. *J Heart Lung Transplant*. Nov 2005;24(11):1710-1720. PMID 16297770
2. CareDx. Overview: AlloMap Testing: Answering Unmet Needs in Heart Transplant Surveillance. n.d.; <http://www.allomap.com/providers/overview/>. Accessed October 1, 2018.

3. Duong Van Huyen JP, Tible M, Gay A, et al. MicroRNAs as non-invasive biomarkers of heart transplant rejection. *Eur Heart J*. Dec 1 2014;35(45):3194-3202. PMID 25176944
4. Patel PC, Hill DA, Ayers CR, et al. High-sensitivity cardiac troponin I assay to screen for acute rejection in patients with heart transplant. *Circ Heart Fail*. May 2014;7(3):463-469. PMID 24733367
5. Organ Procurement and Transplantation Network. National Data. 2018; <https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/#>. Accessed October 1, 2018.
6. Goldberg RJ, Weng FL, Kandula P. Acute and chronic allograft dysfunction in kidney transplant recipients. *Med Clin North Am*. May 2016;100(3):487-503. PMID 27095641
7. Ahmad I. Biopsy of the transplanted kidney. *Semin Intervent Radiol*. Dec 2004;21(4):275-281. PMID 21331139
8. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. *Am J Transplant*. Apr 2008;8(4):753-760. PMID 18294345
9. Haas M. The Revised (2013) Banff Classification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations. *Am J Transplant*. May 2016;16(5):1352-1357. PMID 26696524
10. Celec P, Vlkova B, Laukova L, et al. Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases. *Expert Rev Mol Med*. Jan 18 2018;20:e1. PMID 29343314
11. Phillips M, Boehmer JP, Cataneo RN, et al. Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study). *J Heart Lung Transplant*. Jun 2004;23(6):701-708. PMID 15366430
12. Blue Cross Blue Shield Technology Evaluation Center (TEC). Gene expression profiling as a noninvasive method to monitor for cardiac allograft rejection. *TEC Assessment Program*. 2011;26(8).
13. Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. *Am J Transplant*. Jan 2006;6(1):150-160. PMID 16433769
14. Crespo-Leiro MG, Stypmann J, Schulz U, et al. Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II. *Eur Heart J*. Sep 01 2016;37(33):2591-2601. PMID 26746629
15. Kobashigawa J, Patel J, Azarbal B, et al. Randomized pilot trial of gene expression profiling versus heart biopsy in the first year after heart transplant: early invasive monitoring attenuation through gene expression trial. *Circ Heart Fail*. May 2015;8(3):557-564. PMID 25697852
16. Pham MX, Deng MC, Kfoury AG, et al. Molecular testing for long-term rejection surveillance in heart transplant recipients: design of the Invasive Monitoring Attenuation Through Gene Expression (IMAGE) trial. *J Heart Lung Transplant*. Aug 2007;26(8):808-814. PMID 17692784
17. Pham MX, Teuteberg JJ, Kfoury AG, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. *N Engl J Med*. May 20 2010;362(20):1890-1900. PMID 20413602
18. Bloom RD, Bromberg JS, Poggio ED, et al. Cell-free DNA and active rejection in kidney allografts. *J Am Soc Nephrol*. Jul 2017;28(7):2221-2232. PMID 28280140
19. Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. *J Heart Lung Transplant*. Aug 2010;29(8):914-956. PMID 20643330
20. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. *Kidney Int*. Feb 2010;77(4):299-311. PMID 19847156
21. Centers for Medicare & Medicaid Services. National Coverage Determination for HEARTSBREATH Test for Heart Transplant Rejection (260.10). 2008; [https://www.cms.gov/medicare-coverage-database/details/ncd\\_details.aspx?NCDId=325&ncdver=1&CoverageSelection=National&Keyword=heartsbreath&KeywordLookup=Title&KeywordSearchType=And&clickon=search&bc=gAAAABAAAAAAAA%3d%3d&](https://www.cms.gov/medicare-coverage-database/details/ncd_details.aspx?NCDId=325&ncdver=1&CoverageSelection=National&Keyword=heartsbreath&KeywordLookup=Title&KeywordSearchType=And&clickon=search&bc=gAAAABAAAAAAAA%3d%3d&). Accessed October 1, 2018.
22. Centers for Medicare & Medicaid Services. Local Coverage Determination (LCD): MoIDX: AlloSure® Donor Derived Cell-Free DNA Test (L37266). 2017; [https://www.cms.gov/medicare-coverage-database/details/lcd\\_details.aspx?LCDId=37266](https://www.cms.gov/medicare-coverage-database/details/lcd_details.aspx?LCDId=37266). Accessed October 1, 2018.

23. National Government Services, Inc. (Primary Geographic Jurisdiction 06 & K - Illinois, Minnesota, Wisconsin, Connecticut, New York - Entire State, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont) Local Coverage Determination (LCD): Molecular Pathology Procedures (L35000), Revision Effective Date for services performed on or after 10/01/2018.